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Abstract
Objective: Risk factors are widely used to identify women at risk for gestational diabetes mellitus (GDM) without clear
distinction by pregnancy period or oral glucose tolerance test (OGTT) time points. We aimed to assess the clinical risk
factors for Hyperglycemia in pregnancy (HiP) differentiating by these two aspects.
Design and methods: Nine hundred seventy-one overweight/obese pregnant women, enrolled in the DALI study for
preventing GDM. OGTTs were performed at ≤19 + 6, 24–28 and 35–37 weeks (IADPSG/WHO2013 criteria). Women with
GDM or overt diabetes at one time point did not proceed to further OGTTs. Potential independent variables included
baseline maternal and current pregnancy characteristics. Statistical analysis: Multivariate logistic regression.
Results: Clinical characteristics independently associated with GDM/overt diabetes were at ≤19 + 6 weeks, previous
abnormal glucose tolerance (odds ratio (OR): 3.11; 95% CI: 1.41–6.85), previous GDM (OR: 2.22; 95% CI: 1.20–4.11),
neck circumference (NC) (OR: 1.58; 95% CI: 1.06–2.36 for the upper tertile), resting heart rate (RHR, OR: 1.99; 95% CI:
1.31–3.00 for the upper tertile) and recruitment site; at 24–28 weeks, previous stillbirth (OR: 2.92; 95% CI: 1.18-7.22),
RHR (OR: 3.32; 95% CI: 1.70-6.49 for the upper tertile) and recruitment site; at 35–37 weeks, maternal height (OR:
0.41; 95% CI: 0.20–0.87 for upper tertile). Clinical characteristics independently associated with GDM/overt diabetes
differed by OGTT time point (e.g. at ≤19 + 6 weeks, NC was associated with abnormal fasting but not postchallenge
glucose).
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Conclusion: In this population, most clinical characteristics associated with GDM/overt diabetes were non-modifiable and
differed by pregnancy period and OGTT time point. The identified risk factors can help define the target population for future
intervention trials.

European Journal of Endocrinology
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Endocrinology
(2018) 179, 39–49

Introduction

Subjects and methods

Hyperglycemia in pregnancy (either gestational diabetes
mellitus (GDM) or overt diabetes) is associated with
adverse pregnancy outcomes. GDM, currently defined
by the American Diabetes Association (ADA) as diabetes
diagnosed in the second or third trimester of pregnancy
that is not clearly overt diabetes (1) is mainly associated
with macrosomia and perinatal complications related
to excessive fetal growth (shoulder dystocia, cesarean
section), as well as neonatal and maternal morbidity (2).
The Hyperglycemia And Pregnancy Outcomes (HAPO)
study showed that risk of adverse perinatal outcomes
increased as a function of maternal glycemia, even within
ranges considered normal for pregnancy (3). Recent data,
using the IADPSG/WHO2013 diagnostic criteria (4), reveal
that GDM affects 9–25% of all pregnancies (5).
As GDM, or even overt diabetes in pregnancy, rarely
presents with symptoms, diagnosis is performed by
screening, and clinical risk factors are used to identify it in
early pregnancy (1, 6, 7) or at 24–28 weeks (7). However,
the possibility of differences in risk factors for early vs
later screening have not been addressed in the literature,
probably because screening is usually selective in early
pregnancy (6, 7). Selective screening is mostly based on
weight status, since excess weight is one of the major
identified risk factors for GDM (8), with overweight/obese
women being 2–5.6 times more likely to develop the
condition (9). However, not all overweight/obese women
develop GDM, and being able to determine women at
increased risk within this group could help optimize
screening strategies. In turn, the contribution of different
oral glucose tolerance test (OGTT) time points to GDM
diagnosis significantly differed across centers in the HAPO
study (5), and the reasons are not completely understood.
The main aim of the DALI study was to evaluate
the efficiency of lifestyle intervention and vitamin D
supplementation in reducing gestational weight gain,
fasting plasma glucose (FPG) and improving insulin
sensitivity measured with the homeostasis model
assessment. The specific aim of this analysis was to assess
if clinical factors associated with GDM/overt diabetes
differ by pregnancy period and OGTT time point.

Study population
Nine hundred eighty-four women were recruited to
participate in the DALI study for the prevention of GDM;
only women with OGTT data are included in the current
analysis. The DALI study was a multicenter randomized
controlled trial testing approaches for the reduction in the
risk of GDM, that included: (1) a pilot trial, (2) the DALI
lifestyle study comparing healthy eating (HE), physical
activity (PA) and combined healthy eating and physical
activity (HE&PA) interventions with a control group
and (3) the DALI vitamin D study comparing vitamin D
supplementation with and without HE&PA vs placebo.
Eligibility criteria were prepregnancy BMI ≥29 kg/
m2, ≤19 + 6 weeks of gestation, singleton pregnancy and
age ≥18 years. Gestational age was estimated using selfreported date of last menstrual period, corrected after
ultrasound if required. Exclusion criteria were being unable
to walk at least 100 m safely or to speak the language of
the recruitment site, complex diet requirements and
chronic medical or psychiatric conditions. Women were
recruited in 9 European countries at 11 different sites.
Consent was obtained from each participant after full
explanation of the purpose and nature of all procedures
used in the study. Women diagnosed with overt diabetes
or GDM with IADPSG/WHO 2013 criteria ≤19 + 6 weeks of
gestation were excluded from the randomized trials, but
included in the analyses presented here.
The study was approved by the relevant ethical
committees (NRES Committee East of England – Norfolk:
11/EE/0221; Medical University Poznan: 1165/12; UZ KU
Leuven: ML7625; VUmc Amsterdam: 2012/400; Hospital
De La Santa Creu i Sant Pau Barcelona 13/006 (OBS);
Medical University Vienna: 2022/2012 – 1369/2013;
Region Hovedstaden Copenhagen: H-4-2013-005; Province
of Padua: 4201 Å~ 11; Galway University Hospitals: 7/12).

Data collection
Data from participating women were collected at three
time points: baseline (≤19 + 6 weeks of pregnancy),
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at 24–28 weeks and at 35–37 weeks. At these time
points, blood samples were collected, anthropometric
measurements were performed and participants were
asked to complete different questionnaires.
At each time point, women undertook a standardized,
75 g OGTT in sitting position after a 10-h fast, unless
GDM or overt diabetes had been diagnosed in an earlier
assessment. IADPSG/WH2013 criteria were used (4). Blood
samples were analyzed at local and central laboratories,
with local results being used for clinical management. For
the current analysis, central laboratory values were used
(local data used when central data were unavailable).
Socio-demographic information was collected at
baseline, including maternal age, ethnicity, education,
employment and marital status. Anamnesis included
family history of diabetes in first-degree relatives, active
smoking, polycystic ovarian syndrome (PCOS), chronic
hypertension, previous abnormal glucose tolerance (AGT)
and obstetric history (previous pregnancies, stillbirth,
macrosomia, congenital anomalies, previous GDM).
Physical examination at each visit included
measurements of resting heart rate (RHR), and
anthropometrics including height, weight, BMI and neck
circumference (NC). RHR was measured with an electronic
blood pressure monitor after 5 min of rest (average value
of two measurements taken 1-min apart). Prepregnancy
weight was based on self-report, using the earliest antenatal
weight when prepregnancy weight was not known. Height
was measured at baseline with a stadiometer. Height
measurement and prepregnancy weight were used to
calculate BMI (kg/m2), to determine inclusion criteria. In
the next time points, women were weighed on calibrated
electronic scales and BMI was calculated in each visit. NC,
a central adiposity index, was considered because of its
association with various cardiovascular risk factors (10),
and insulin resistance (11), its easy measurement (12)
and independent association with pregnancy-induced
hypertension and preeclampsia (13). NC was measured in
a standing relaxed upright position between mid-cervical
spine and mid-anterior neck, to within 1 mm (12). Taking
into account information in the literature, the season
during which the OGTT was performed (14) and newborn
sex (15) was also addressed.
Outcome variable: GDM or overt diabetes according
to IADPSG/WHO2013 criteria (FPG ≥5.1 mmol/L and/or
1-h plasma glucose (PG) ≥10 mmol/L and/or 2 h PG
≥8.5 mmol/L).
Potential Hyperglycemia in pregnancy (HiP) risk
factors studied were first-degree family history of diabetes,
maternal age, ethnicity, education, employment, marital
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status, active smoking, chronic hypertension, PCOS,
previous AGT, previous pregnancies, previous stillbirth,
previous macrosomia, previous congenital anomalies,
previous GDM, maternal weight and BMI at different
pregnancy periods, height, NC, RHR, recruitment site,
newborn sex, season when OGTT was performed and
(at 24–28 and 35–37 weeks) study intervention.

DALI interventions
HE and PA interventions used motivational interviewing
method. The HE intervention aimed to promote a diet
lower in simple and complex carbohydrate, lower fat,
limited intake of total calories while keeping protein
intake and increasing fiber. The PA intervention was
in line with American College of Obstetricians and
Gynecologists (ACOG) guidelines and promoted both
aerobic and resistance PA. The vitamin D intervention
used a supplementation of 1600 IU/day of vitamin D3 on
top of pregnancy vitamins taken by the women (16).
The trial registration number is ISRCTN70595832 and
the detailed protocol has already been published (16).

Statistical analyses
Categorical data are presented as counts and percentages,
and continuous data as mean and standard deviation or
as median and interquartile range for data not normally
distributed.
Overall prevalence of GDM/overt diabetes was
calculated as the rate of women with a GDM/overt
diabetes diagnosis among those with glucose data. The
overall prevalence per protocol was calculated as the rate
of women with a GDM/overt diabetes diagnosis among
those completely adhering to the study protocol (all
expected OGTTs performed by the last day of pregnancy).
First, a bivariate logistic regression was performed
for potential GDM/overt diabetes risk factors at each
pregnancy period and OGTT time point. Factors with a
two-sided P value <0.10 were included in a multivariate
backward logistic regression model to identify
independent variables and calculate the corresponding
OR. Barcelona was empirically chosen as the reference
site. The components of the DALI intervention (HE,
PA, vitamin D) were dealt with as different variables.
Significance was defined as a two-sided P < 0.05. The ORs
for continuous independent variables were turned into
tertiles to assess their relevance in clinical terms.
To test the performance of the models obtained,
receiver-operating characteristic curves (ROC) were
www.eje-online.org
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performed, and the area under the ROC curve (AUROC)
was calculated for each pregnancy period.
Two different sensitivity analyses were performed.
The first sensitivity analysis was performed at each
pregnancy period using prepregnancy weight and BMI
and standardized changes in weight (Δ weight) and
BMI (Δ BMI) from prepregnancy instead of particular
measurements at each point. Δ weight was defined as
the standardized difference between maternal weight at
24–28 or 35–37 weeks and prepregnancy weight. Δ BMI
was defined as the standardized difference between BMI
at 24–28 or 35–37 weeks and prepregnancy BMI.
A second sensitivity analysis was performed using
mixed-effects logistic regression model with center as a
group variable.
All statistical analyses were performed with the
statistical package IBM SPSS Statistics (IBM Corp, version
20.0), except for the mixed-effects logistic regression that
was performed with STATA.

Results
Of the 984 women recruited, glucose values were not
available in 13 women, leaving 971 women for the
analysis. Detailed maternal anamnestic and sociodemographic factors are shown in Table 1. Changing
maternal characteristics and OGTT results at the different
periods of pregnancy studied are described in Table 2.
Figure 1 shows the flux diagram for recruitment and
inclusion at each pregnancy period.

GDM/overt diabetes prevalence
At ≤19 + 6 weeks 27.9% women were diagnosed with
diabetes (27% GDM and 0.9% overt diabetes). Glycemia
leading to diagnosis was FPG in most cases (81.2%).
At 24–28 weeks of pregnancy, diabetes was diagnosed
in 15.5% of 580 previously glucose-tolerant participants
(15.3% GDM and 0.2% overt diabetes). Diabetes was
diagnosed in 57.8% of the participants by FPG.
At 35–37 weeks, diabetes was diagnosed in 15.2% of
422 previously glucose-tolerant women (15.2% GDM).
GDM was diagnosed in 42.2% by FPG.
Overall, 425 out of 971 women with glucose data
(43.8%) presented GDM/overt diabetes. In women
completely adhering to the study protocol, the prevalence
of GDM/overt diabetes was 52.4% (425 out of 811
participants).
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GDM/overt diabetes risk factors in different periods
of pregnancy and OGTT time points
At ≤19 + 6 weeks of gestation
At this assessment, previous AGT, previous GDM, NC, RHR
and recruitment site were significantly associated with
GDM/overt diabetes in the multivariate logistic regression
analysis (Table 3). The direction of the association
was positive for all risk factors with the exception of
recruitment site with ORs ranging from 0.12 to 0.83.
Among factors associated with overall GDM/overt
diabetes, different risk factors were associated with glucose
Table 1 Prepregnancy and pregnancy characteristics of
women recruited to participate in the DALI study.
Values, %,
mean (±s.d.) or
median (IQR)

Characteristic

Family history
First-degree relative with diabetes (Y)
Age, ethnicity and socioeconomic
characteristics
Maternal age (years)
Ethnicity (Caucasian) (Y)
Education (high) (Y)
Marital status (with partner) (Y)
Working status (Y)
Smoking and clinical conditions
PCOS (Y)
Chronic hypertension (Y)
Active smoking (Y)
Previous abnormal glucose
tolerance (Y)
Obstetric history
Previous pregnancies (Y)
Previous gestational diabetes
mellitus (Y)
Previous stillbirth (Y)
Previous congenital malformations (Y)
Previous macrosomia (Y)
Anthropometrics
Height (cm)
Prepregnancy weight (kg)
Prepregnancy BMI (kg/m2)
Current pregnancy-related variables
(% participants)
Site (Y)
  Spain
  Austria
  Belgium
   Denmark (Copenhagen, Odense)
  Poland
   Italy (Padua, Pisa)
  Ireland
  The Netherlands
   The United Kingdom
Male newborn sex (male) (Y)

24.6
32.1 (±5.3)
86.4
55.1
93.5
78.3
10.3
12.5
16.6
4.0
62.7
6.5
7.1
2.5
13.3
166 (161–170)
83.5 (91–100)
33.0 (30.5–36.3)

9.5
11.0
9.7
20.3
9.9
10.8
7.9
8.0
11.9
51.5

IQR, interquartile range; PCOS, polycystic ovarian syndrome; Y, Yes.
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Table 2 Maternal characteristics and OGTT results at different periods of pregnancy. Values are expressed in %, mean ± s.d. or
P50 (P25–P75)

European Journal of Endocrinology

Characteristic

Weight (kg)
BMI (kg/m2)
Neck circumference (cm)
Resting heart rate (bpm)
Weight gain (kg)†
BMI gain (kg/m2)†
Active smoking (Y)
Season when OGTT was performed (Y)
Spring
Summer
Autumn
Winter
DALI intervention (Y)‡
Healthy eating
Physical activity
Vitamin D
Control
Plasma glucose concentrations (mmol/L)
Fasting glucose
1-h glucose
2-h glucose
GDM/overt diabetes new diagnosis (Y)
GDM/overt diabetes diagnosis by OGTT
time point (%)
Fasting glucose
1-h glucose
2-h glucose

<19 + 6 weeks (n = 971)*

94.0 (85.4–103.2)
33.8 (31.7–37.0)
36.2 (35.0–37.9)
80.0 (73–87)
1.8 (−0.4 to 4.2)
0.64 (−0.14 to 1.55)
16.6
28.3
28.2
24.4
19.2

4.7 (4.4–5)
7.0 (5.9–8.3)
6.0 (5.2–6.9)
27.9
81.2
12.9
5.9

24–28 weeks (n = 580)*

96.4 (89.5–105.4)
34.9 (33.0–37.9)
36.0 (34.9–37.9)
84.0 (77–91)
5.6 (2.2–9.1)
1.95 (0.79–3.40)

35–37 weeks (n = 422)*

100.4 (92.8–110.3)
36.6 (34.1–39.4)
36.5 (35.2–38.0)
87.0 (79.0–93.0)
9.2 (5.1–13.7)
3.36 (1.87–4.96)
12.3

22.3
27.4
26.9
23.5

25.2
23.6
30.5
20.8

51.7
52.6
10.5
21.0

52.6
50.9
10.9
21.1

4.5 (4.3–4.8)
7.5 (6.6–8.7)
6.1 (5.4–6.9)
15.5
57.8
33.3
8.9

4.4 (4.2–4.7)
8.0 (7.0–8.9)
6.3 (5.6–7.2)
15.2
42.2
37.5
20.3

*n only includes women with available glucose values at first assessment and without a previous GDM/overt diabetes diagnosis afterwards; †used in the
sensitivity analysis instead of weight and BMI; ‡percentages sum more than 100% because of combined interventions.
GDM, gestational diabetes mellitus; OGTT, oral glucose tolerance test; Y, yes.

values over the cut-off at different OGTT time points
(Table 3). That is, NC and recruitment site were associated
with abnormal FPG but not with postchallenge PG, RHR
with abnormal postchallenge PG, but not with FPG, while
previous AGT was associated with both abnormal fasting
and postchallenge PG (Table 3).
The ORs for GDM/overt diabetes of continuous
variables turned into tertiles were for NC, 0.92 (95% CI:
0.61–1.39, P = 0.68), for the second tertile (35.4–37.2 cm,
n = 326) and 1.58 (95% CI: 1.06–2.36, P = 0.02) for the
upper tertile (>37.2 cm, n = 315); and for RHR, 1.49
(95% CI: 1.00–2.23, P = 0.05) for the second tertile (75 to
84 bpm, n = 318) and 1.99 (95% CI: 1.31–3.00, P = 0.001)
for the upper tertile (>84 bpm, n = 293).
The AUROC for the model at ≤19 + 6 weeks of
pregnancy was 0.74 (95% CI: 0.70–0.77, P < 0.001) (Fig. 2).

associated with GDM/overt diabetes (Table 3). The direction
of the association was positive for unexpected stillbirth and
RHR but not for recruitment site (OR: 0.09–0.78).
Among factors associated with both overall
GDM/overt diabetes and abnormal PG at specific OGTT
time points, stillbirth in a prior pregnancy was associated
with postchallenge PG, while RHR was associated with
both abnormal fasting and postchallenge PG (Table 3).
The ORs for GDM/overt diabetes for tertiles of RHR
were 1.83 (95% CI: 0.93–3.60, P = 0.08), for the second
tertile (80–88 bpm, n = 184) and 3.32 (95% CI: 1.70–6.49,
P < 0.001) for the upper tertile (>88 bpm, n = 182).
The AUROC for the model between 24 and 28 weeks
of pregnancy was 0.71 (95% CI: 0.65–0.78, P < 0.001)
(Fig. 2).
At 35–37 weeks of gestation

At 24–28 weeks of gestation
In the multivariate analysis, stillbirth in a prior pregnancy,
RHR and recruitment site were the independent variables

At this gestational age, only maternal height was
(negatively) associated with GDM/overt diabetes in the
multivariate logistic regression analysis (Table 3) but did
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In this analysis of the DALI study, we report that
different clinical risk factors are associated with GDM/
overt diabetes at different pregnancy periods and OGTT
time points. At first assessment previous GDM, previous
AGT and NC were associated with GDM/overt diabetes,
alongside recruitment site and RHR. The last two
variables, as well as previous stillbirth were also associated
with GDM/overt diabetes at 24–28 weeks, whereas in late
pregnancy, only maternal height was identified. As for
the different OGTT time points, we observed that NC and
recruitment site were associated with FPG, stillbirth with
abnormal postchallenge PG and prior AGT and RHR with
both abnormal FPG and postchallenge PG.

GDM/overt diabetes prevalence
Figure 1
Flux diagram for recruitment and inclusion at different

European Journal of Endocrinology

pregnancy periods. GDM, gestational diabetes mellitus.

not achieve significance for the individual time points. The
ORs for GDM/overt diabetes for tertiles of maternal height
were 0.99 (95% CI: 0.54–1.83, P = 0.98) for the second
tertile (163–169 cm, n = 200 and 0.41 (95% CI: 0.20–0.87,
P = 0.02)) for the upper tertile (>169 cm, n = 195).
The AUROC for the model between 35 and 37 weeks
of pregnancy was 0.60 (95% CI: 0.53–0.68, P = 0.009)
(Fig. 2).

Sensitivity analysis
In the first sensitivity analysis, ΔBMI was added to the
models for abnormal FPG and GDM/overt diabetes after
any OGTT time point at 24–28 weeks of pregnancy (details
not shown with a nominal improvement in the AUROC
for this period (AUROC = 0.726, 95% CI: 0.667–0.785).
In the second sensitivity analysis, the mixed-effects
logistic regression showed that center continue to be
significant both at <19 + 6 and 24–28 weeks and the
magnitude of the effect for other independent variables
was similar.

Discussion
Overweight and obesity are major risk factors for GDM
and their prevalence among women of reproductive age is
on the rise. Identifying risk factors for GDM in earlier or
later periods of pregnancy could help optimize screening
strategies and interventions.

The prevalence of GDM/overt diabetes in the participants
of the DALI study was high (43.8%), information that has
already been reported (17, 18). The variation in the figures
herein described is attributable to the use of central lab
values in this report.

Clinical risk factors associated with GDM/overt
diabetes after any OGTT time point in different
periods of pregnancy
The DALI study has published two reports where risk
factors for GDM have been addressed (17, 18) but not
specifically in the three study pregnancy periods and
OGTT time points as in the current study.
At ≤19 + 6 weeks, the identified risk factors for GDM/
overt diabetes were previous AGT, previous GDM, NC,
RHR and recruitment site. All these variables have been
reported in the literature as associated with overall GDM
(diagnosed at any time during pregnancy).
The association of previous GDM with GDM diagnosed
before 24 weeks of pregnancy has been described (19), and
it is the only risk factor considered by the current NICE
guidelines to qualify for GDM testing in early pregnancy (7).
We are not aware of studies addressing NC, previous
AGT, RHR or recruitment site at first assessment.
Central adiposity and specifically NC has been reported
to confer additional risk for AGT beyond BMI both in (20)
and outside pregnancy (10). In the UPBEAT trial, neck/
thigh ratio superseded BMI, as an independent variable
for GDM at 27–28 weeks (21). Our study confirms that
NC out-performs BMI itself as risk factor for GDM/overt
diabetes, in overweight/obese women and shows for the
first time that this association is present at ≤19 + 6 weeks.
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0.11 (0.05–0.24)

1.04* (1.01–1.071)

P

2.47 (1.07–5.7)

OR (95% CI)

Fasting

4.18 (1.68–10.38)
1.04* (1.0–1.07)

1.05* (1.02–1.08)

OR (95% CI)

1h

0.002
0.029

0.001

P

1.05* (1.02–1.09)

2.89 (1.02–8.18)

OR (95% CI)

2h

0.001

0.046

P

0.021
0.001

0.007
0.03

1
0.33 (0.13–0.89)
0.15 (0.05–0.49)
0.27 (0.08–0.86)
0.78 (0.26–2.30)
0.09 (0.03–0.32)
0.65 (0.22–1.93)
0.20 (0.05–0.87)
0.20 (0.06–0.69)
0.34 (0.11–1.04)
0.38 (0.15–0.96)
0.96 (0.92–0.99)

<0.001
2.92 (1.18–7.22)
1.05* (1.02–1.07)

1
0.21 (0.11–0.41)
0.22 (0.11–0.44)
0.83 (0.46–1.49)
0.19 (0.09–0.42)
0.14 (0.07–0.29)
0.12 (0.05–0.30)
0.27 (0.11–0.66)
0.13 (0.06–0.28)
0.38 (0.19–0.76)
0.14 (0.07–0.28)

0.001
0.001

0.011

2.22 (1.2–4.11)
1.15* (1.06–1.24)
1.03* (1.01–1.05)

0.005

P

3.11 (1.41–6.85)

OR (95% CI)

GDM/overt diabetes after any OGTT
time point

L C Mendoza, J Harreiter
and others
Gestational diabetes risk factors
179:1

*Corresponding ORs for tertiles of these variables are shown in the ‘Results’ section.
GDM, gestational diabetes mellitus; OGTT, oral glucose tolerance test; OR, odds ratio; Y, yes.

≤19 + 6 weeks of gestational age
Previous abnormal glucose
tolerance (Y)
Previous gestational diabetes
mellitus (Y)
Neck circumference (cm)
Resting heart rate (bpm)
Recruitment site
  Spain
  Austria
  Belgium
  Denmark-Copenhagen
  Denmark-Odense
  Poland
  Italy-Padua
  Italy-Pisa
  Ireland
  The Netherlands
   The United Kingdom
24–28 weeks of gestational age
Previous stillbirth (Y)
Resting heart rate (bpm)
Recruitment site
  Spain
  Austria
  Belgium
  Denmark-Copenhagen
  Denmark-Odense
  Poland
  Italy-Padua
  Italy-Pisa
  Ireland
  The Netherlands
   The United Kingdom
35–37 weeks of gestational age
Height (cm)

Independent variables for
GDM/overt diabetes

(at 24–28 and 35–37 weeks of gestational age) DALI intervention

malformations, previous macrosomia, maternal age, height, weight, BMI, neck circumference, recruitment site, newborn sex, season when OGTT was performed and

hypertension, active smoking, previous abnormal glucose tolerance, previous pregnancies, previous gestational diabetes, previous stillbirth, previous congenital

analysis. Variables used for the model: first-degree relative with diabetes, ethnicity, education, marital status, working status, polycystic ovarian syndrome, chronic

Table 3 Clinical risk factors for gestational diabetes/overt diabetes at different periods of pregnancy in different OGTT time points. Multivariate logistic regression
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Figure 2
Receiver-operating characteristic curves for GDM/overt DM
models after clinical factors with assessment of maternal size
using measurements during pregnancy. (A) at ≤19 + 6 weeks of
gestational age, (B) between 24 and 28 weeks, (C) and
between 35 and 37 weeks. GDM, gestational diabetes

European Journal of Endocrinology

mellitus; ROC, receiver-operating characteristic curve.

RHR has been validated as a proxy for fitness status
(22) but has not been directly addressed as a risk factor
for GDM. We herein report for the first time that
increasing RHR is a risk factor for GDM/overt diabetes
at <19 + 6 weeks. According to the observed ORs
expressed for tertiles of RHR and NC, RHR has a larger
contribution for identifying GDM/overt diabetes at this
gestational age.
A large variation in the prevalence of diabetes among
different locations is widely known, both in and outside
pregnancy (5, 23, 24). In the current analysis, we have
observed an eight-fold difference in the risk of GDM/overt
diabetes between centers, but it did not fit the previously
reported Atlantic-to-Mediterranean gradient in prevalence
(24). However, we have to take into account that the
Atlantic-to-Mediterranean gradient referred to absolute
prevalence. Even more intriguing, different sites of the
same country (i.e. Copenhagen vs Odense in Denmark)
displayed different ORs for GDM/overt diabetes. Genetic,
environmental and/or lifestyle factors such as diet or
pollution could be responsible for these differences.
Although the use of IADPSG criteria to diagnose GDM
before 24–28 weeks has recently been challenged due to
the physiological decrease of FPG from early pregnancy
to 24–28 weeks, this is not the case for obese women (25).
Thus, we assume that if we had not used IADPSG criteria
at first assessment, risk factors for GDM at ≤19 + 6 would
translate into risk factors at 24–28 weeks.
At 24–28 weeks of pregnancy, the independent
variables for GDM/overt diabetes were previous stillbirth,
RHR and recruitment site.
The current observation of prior stillbirth conferring
a ≈three-fold higher risk of GDM/overt diabetes at
24–28 weeks is in line with information in the literature
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reporting unexplained stillbirth to be a risk factor for
AGT/GDM in a subsequent pregnancy (OR: 4.52) (26).
PA has been linked with a lower risk of GDM (27)
while exercise intervention trials have shown differing
impact in GDM prevalence (28, 29). In the DALI study
itself, the PA group showed no improvement in the rate of
GDM (30). As the PA intervention did not have an impact
on RHR at 24–28 or 35–37 weeks (data not shown), this
could explain the lack of benefit of PA intervention on
metabolic outcomes.
The discussion on recruitment site as a risk factor for
GDM/overt diabetes at ≤19 + 6 weeks would also apply here.
At 35–37 weeks of gestational age, maternal height,
a non-modifiable risk factor, was the only independent
variable associated with GDM/overt diabetes. Maternal
height is also a known risk factor for GDM, showing an
inverse association (31). As to the underlying mechanisms,
components of stature, specifically leg length, are
inversely associated with insulin secretion and sensitivity
(32). The relevance of identifying risk factors for GDM/
overt diabetes at 35–37 weeks is unclear as the impact of
hyperglycemia diagnosed at this stage is unknown.
Sensitivity analysis
In the sensitivity analysis ∆ BMI was an independent
variable for GDM/overt diabetes at 24–28 weeks. This
indicates the contribution of ∆ weight during pregnancy
and the potential to address it for GDM prevention
despite the fact that this approach has not been successful
in DALI among other trials (33).

Clinical risk factors for abnormal PG at different OGTT
time points
The relevance of abnormal glucose levels at different
OGTT time points comes from their different impact on
outcomes, from their relative contribution to the GDM
diagnosis itself (3), and for different pathophysiology
since subjects with impaired FPG display basal insulin
resistance (34, 35) while subjects with impaired glucose
tolerance display impaired insulin secretion (34).
In pregnancy, a single study showed that FPG was
associated with maternal weight, 1 h PG was associated
with maternal weight, height, parity and socioeconomic
condition, while no associations with 2 h PG were
identified (35). In our study, different methods and
covariates were used but both studies concur in that
fasting and postchallenge PGs are associated with different
variables.
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We have observed that NC was associated with
abnormal FPG at ≤19 + 6 weeks of pregnancy. In nonpregnant women, NC is associated with FPG (10) but in
pregnancy, its relationship with specific OGTT time points
had not been previously described.
Previous AGT was associated with a ≈two-fold risk of
abnormal FPG and ≈three-fold risk of abnormal 2 h PG in
the first assessment, which is not surprising, considering
that the definition of AGT includes both impaired FPG
and postchallenge PG.
RHR was associated with abnormal postchallenge PG
at <19 + 6, and with both fasting and postchallenge PG
at 24–28 weeks. Measures of cardiorespiratory fitness are
mainly associated with postchallenge PG both outside
and during pregnancy (29, 36). Our results indicate that
in pregnant women, surrogates of exercise also display
favorable associations with FPG but preferentially with
postchallenge PG.
Recruitment site was an independent variable
for GDM/overt diabetes at first assessment due to its
association with abnormal FPG. This is in line with the
HAPO study, where adjusting for BMI did not eliminate
differences between sites in abnormal FPG suggesting that
other unknown site-related factors had an impact on FPG
(5).
At 24–28 weeks of gestation, previous stillbirth was
associated with abnormal 1-h PG. This would be in
agreement with the post hoc analysis of the aspart trial
in women with type 1 DM where spikes of high glucose
values in the third trimester were associated with poor
late pregnancy outcomes including stillbirth (37).
Thus, we have identified that distinct clinical
characteristics are associated with abnormal PG at
different OGTT time points.
There is a growing interest to identify women who
will develop GDM in order to either use selective screening
approaches or to test prevention strategies. In high-risk
populations, AUROCs as high as 0.88 have been reported
for early GDM (19) and 0.82 for GDM at 24–28 weeks (38).
In our opinion, the AUROC curves observed in the current
report (0.74 at first assessment and 0.71 at 24–28 weeks)
do not support selective screening among an overweight/
obese population at any of these periods. The study was
conducted in a group of overweight/obese women; thus,
we have not addressed the use of overweight/obesity vs
normal weight as a risk factor for GDM/overt diabetes.
However, observations from the current study can help
identify women at risk as well as modifiable risk factors
for GDM. The association between NC and RHR (adiposity
and fitness proxies), with GDM/overt diabetes diagnosed
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before 20 weeks of gestation indicate, that in overweight/
obese women, lifestyle changes including diet and exercise,
may need to be implemented before conception to have a
positive impact in metabolic outcomes at these gestational
age. Clinical risk factors for GDM/overt diabetes in women
not diagnosed at first assessment may help to identify a
target population for preventive interventions during
pregnancy and even the intervention itself (i.e. safe
exercise aiming at reducing RHR).
The main strength of this study is the universal GDM/
overt diabetes screening at different pregnancy periods
unless earlier diagnosis had been performed, which
allows to identify risk factors for real incident GDM
cases. The study population size and the multicenter
setting are additional strengths being representative of
the European overweight/obese population. The use at
first assessment of IADPSG criteria, currently challenged,
can be considered a weakness but right now there are no
validated criteria for this gestational age. Self-reported
data on prepregnancy weight and previous stillbirth
could be considered additional weaknesses. The study was
conducted in a group of overweight/obese women, which
limits the results interpretation to this specific population.
It could be argued that the DALI interventions could
have influenced the risk factors identified. However, this
is unlikely, since DALI interventions were included as
potential independent variables in our analysis.
Overall, in women with a prepregnancy BMI ≥29 kg/
2
m , the prevalence of GDM/overt diabetes after IADPSG/
WHO2013 was very high, most associated clinical
characteristics were non-modifiable, differed by pregnancy
period and OGTT time point, and the AUROCs did not
support selective screening. The identified clinical risk
factors can help define the target population for future
intervention trials with RHR making a new attractive
candidate for both identification and intervention.
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